Unity Biotechnology Stock Price, News & Analysis (NASDAQ:UBX)

-0.07 (-1.00 %)
(As of 09/23/2019 07:43 AM ET)
Today's Range
Now: $6.90
50-Day Range
MA: $6.62
52-Week Range
Now: $6.90
Volume412,288 shs
Average Volume267,504 shs
Market Capitalization$298.08 million
P/E RatioN/A
Dividend YieldN/A
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc and changed its name to Unity Biotechnology, Inc in January 2015. Read More…

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:UBX



Sales & Book Value

Annual SalesN/A



Market Cap$298.08 million
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable

Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.

Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology Inc (NASDAQ:UBX) announced its earnings results on Wednesday, August, 7th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.10. View Unity Biotechnology's Earnings History.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Unity Biotechnology.

What price target have analysts set for UBX?

3 brokerages have issued 1 year target prices for Unity Biotechnology's shares. Their predictions range from $14.00 to $21.00. On average, they anticipate Unity Biotechnology's stock price to reach $17.50 in the next year. This suggests a possible upside of 153.6% from the stock's current price. View Analyst Price Targets for Unity Biotechnology.

What is the consensus analysts' recommendation for Unity Biotechnology?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Unity Biotechnology.

What are Wall Street analysts saying about Unity Biotechnology stock?

Here are some recent quotes from research analysts about Unity Biotechnology stock:
  • 1. According to Zacks Investment Research, "UNITY Biotechnology Inc. develops therapeutics which prevents, halts and reverses various diseases. The company's product portfolio includes UBX101, is designed to treat musculoskeletal disease with an initial focus on osteoarthritis. UNITY Biotechnology Inc. is based in California, United States. " (5/14/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We are initiating coverage on UNITY Overweight rating and 12-month PT of $21. UNITY is making progress on treatments that could extend healthspan, a longer disease-free state, by targeting indications that are associated with aging. UNITY focuses on eliminating senescent cells, the precursors to disease progression. Lead product UBX0101 is in Phase 1 development for osteoarthritis (OA), with proof-of-concept data expected in 2Q19." (3/6/2019)

Has Unity Biotechnology been receiving favorable news coverage?

News articles about UBX stock have trended somewhat negative on Monday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Unity Biotechnology earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Unity Biotechnology.

Are investors shorting Unity Biotechnology?

Unity Biotechnology saw a drop in short interest in August. As of August 31st, there was short interest totalling 4,879,500 shares, a drop of 11.4% from the July 31st total of 5,509,100 shares. Based on an average daily volume of 283,900 shares, the short-interest ratio is presently 17.2 days. Approximately 23.1% of the company's stock are short sold. View Unity Biotechnology's Current Options Chain.

Who are some of Unity Biotechnology's key competitors?

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Canopy Growth (CGC), Acceleron Pharma (XLRN), Target (TGT), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), JD.Com (JD), Biohaven Pharmaceutical (BHVN), CEL-SCI (CVM) and Standard Life Aberdeen (SLA).

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the folowing people:
  • Mr. Keith R. Leonard Jr., Exec. Chairman & CEO (Age 57)
  • Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 51)
  • Mr. Robert C. Goeltz II, Chief Financial Officer (Age 46)
  • Dr. Jan M. van Deursen, Founder
  • Dr. Judith Campisi, Founder

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Who are Unity Biotechnology's major shareholders?

Unity Biotechnology's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.61%), EcoR1 Capital LLC (2.42%), Vanguard Group Inc. (1.50%), Northern Trust Corp (0.56%), Citadel Advisors LLC (0.55%) and Morgan Stanley (0.26%).

Which major investors are selling Unity Biotechnology stock?

UBX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Vanguard Group Inc. and BNP Paribas Arbitrage SA.

Which major investors are buying Unity Biotechnology stock?

UBX stock was bought by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, EcoR1 Capital LLC, Sio Capital Management LLC, BlackRock Inc., Susquehanna International Group LLP, Moloney Securities Asset Management LLC, Virtus ETF Advisers LLC and Ellington Management Group LLC.

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $6.90.

How big of a company is Unity Biotechnology?

Unity Biotechnology has a market capitalization of $298.08 million. Unity Biotechnology employs 106 workers across the globe.View Additional Information About Unity Biotechnology.

MarketBeat Community Rating for Unity Biotechnology (NASDAQ UBX)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  85 (Vote Underperform)
Total Votes:  163
MarketBeat's community ratings are surveys of what our community members think about Unity Biotechnology and other stocks. Vote "Outperform" if you believe UBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UBX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel